Shire is a biotechnology company that researches, develops, licenses, manufactures, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The Company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Shire markets its products through wholesalers, distributors, and various pharmacies.
Type
Public
HQ
Dublin, IE
Founded
1986
Size (employees)
23,044 (est)-3%
Website
shire.com
Shire was founded in 1986 and is headquartered in Dublin, IE
Report incorrect company information

Key People/Management at Shire

Flemming Ornskov

Flemming Ornskov

CEO
Thomas Dittrich

Thomas Dittrich

CFO
Andreas Busch

Andreas Busch

Head of Research and Development and Chief Scientific Officer
Bill Mordan

Bill Mordan

General Counsel and Company Secretary
Joanne Cordeiro

Joanne Cordeiro

Chief Human Resources Officer
Perry Sternberg

Perry Sternberg

Head of US Commercial
Show more

Shire Office Locations

Shire has offices in Hanoi, Guaynabo, Cambridge, Bannockburn and in 48 other locations
Dublin, IE (HQ)
50 Baggot Street Lower
Sydney, AU
225 George St
Wien, AT
67 Industriestraße
Bruxelles, BE
47 Rue Montoyer
Chácara Santo Antonio (Zona Sul), BR
Av. das Nações Unidas, 14.171
Sofia, BG
2 2a ul. "Saborna"
Show all (53)
Report incorrect company information

Shire Financials and Metrics

Shire Revenue

Shire's revenue was reported to be $15.16 b in FY, 2017 which is a 39.3% increase from the previous period.
USD

Market capitalization (16-Aug-2018)

52.3 b

Closing stock price (16-Aug-2018)

171.5
Shire's current market capitalization is $52.3 b.
Annual
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.5 m4.7 m14.1 m18.2 m26.5 m19.2 m20.1 m29 m32.4 m119.6 m108 m98.3 m114 m111.4 m103.4 m109.3 m120.6 m122.3 m67.1 m58.2 m47.6 m15.2 b

Revenue growth, %

(9%)16%(2%)(7%)6%10%1%(45%)9467%70%39%

Cost of goods sold

4.7 b

Gross profit

10.5 b
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.5 b1.6 b1.7 b1.7 b2.4 b3.5 b3.6 b3.7 b3.5 b

Cost of goods sold

227.8 m228 m262.7 m248.6 m778.1 m1.7 b1.3 b1.1 b1 b

Gross profit

1.3 b1.3 b1.4 b1.5 b1.7 b1.7 b2.2 b2.6 b2.5 b

Gross profit Margin, %

85%85%84%85%68%50%63%70%72%
Annual
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

45.7 k219.3 k17 k4 k135.5 m528.8 m472.4 m

Accounts Receivable

5 k4 k1.2 b2.6 b3 b

Prepaid Expenses

197.4 m806.3 m795.3 m

Inventories

455.3 m544.8 m635.4 m3.6 b3.3 b
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

74.3 m64 m44.9 m69 m693.4 m728.6 m369 m263.7 m209.3 m

Accounts Receivable

1.1 b1.1 b1.3 b1.3 b2.4 b2.6 b2.6 b2.8 b2.8 b

Prepaid Expenses

216.6 m221.6 m215 m314.4 m733.6 m665.3 m787.2 m778.5 m779.9 m

Inventories

588.7 m632.8 m608.9 m680 m5.8 b4.9 b3.3 b3.3 b3.4 b
Annual
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(939.6 k)(1.9 m)1.2 m(762 k)(179 k)(12.2 m)(9.8 m)(15.1 m)(10.5 m)5.7 m(65.5 m)7.5 m15.1 m4.7 m(1.9 m)(2.7 m)1.6 m1.6 m(2.9 m)2.9 m2.5 m4.3 b

Depreciation and Amortization

324.4 m407.3 m637.2 m1.5 b2.3 b

Inventories

(63.2 m)(255.8 m)(145.1 m)

Accounts Payable

109.2 m621.6 m(526.8 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

410.4 m570 m1 b419 m256.9 m(129.9 m)375 m615.3 m1.2 b

Depreciation and Amortization

120.6 m291.8 m457.4 m168.9 m429.8 m877.8 m486.9 m1 b1.6 b

Inventories

(22 m)(37.4 m)(21.7 m)(32.2 m)(116.4 m)(228 m)(151.8 m)(171.6 m)(245.2 m)

Accounts Payable

77.5 m(39.8 m)56.5 m(154.6 m)342.7 m315.2 m(671.5 m)(445.1 m)(557.8 m)
Show all financial metrics

Shire Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Phase I Trials Products

7 6 6 7

Phase II Trials Products

11 6 10 10

Phase III Trials Products

7 14 17 15

Phase Approved

2 3 4 7
Show all operating metrics

Shire Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Baxalta January 11, 2016$32 b
Dyax November 02, 2015$5.90 b
Foresight Biotherapeutics August 03, 2015$300 m
Meritage Pharma February 24, 2015$245 m
NPS Pharmaceuticals, Inc. January 11, 2015$5.20 b
Lumena Pharmaceuticals May 13, 2014$260 m
Fibrotech Therapeutics May 02, 2014$75 m
ViroPharma Incorporated November 11, 2013$4.20 b
SARcode Bioscience March 25, 2013$160 m
Premacure March 12, 2013
Show more

Shire Revenue Breakdown

Embed Graph

Shire revenue breakdown by business segment: 11.6% from Internal Medicine, 30.2% from Immunology, 18.4% from Neuroscience, 10.0% from Genetic Diseases, 26.2% from Hematology and 3.6% from Other

Human Capital Metrics

Shire's employees are reported to be approximately 52% female and 48% male.
Embed Graph
Show all human capital metrics
Report incorrect company information

Shire Online and Social Media Presence

Embed Graph
Report incorrect company information

Shire News and Updates

Merrimack Reports Second Quarter 2018 Financial Results

CAMBRIDGE, Mass., Aug. 7, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its second quarter 2018 financial results for the period ended June 30, 2018. "A cornerstone of...

Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding

Enterome CEO to Present at Two Upcoming Investor Conferences in the United States

PARIS and CAMBRIDGE, Massachusetts, August 2, 2018 /PRNewswire/ -- Enterome SA, a clinical-stage biotechnology company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications, announces...

'Lord of the Rings' TV series writers announced

Amazon Studios has roped in JD Payne and Patrick McKay to pen their highly anticipated mega-budget "Lord of the Rings" TV series. Their writing credits include the upcoming "Star Trek 4" for Paramount and adapting the upcoming "Jungle Cruise" for Disney. "The rich world that J R R. Tolkien created i…
Show more
Report incorrect company information

Shire Company Life and Culture

Report incorrect company information